tirzepatide for heart health The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist SUMMIT: Tirzepatide Improves Outcomes and
Description
GLP-1 receptor agonists like semaglutide show modest blood pressure reduction in clinical trials, primarily through weight loss
rates: 3.64 versus 4.82
One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition that can lead to sudden vision loss due to lack of blood flow.
Discover personalized compounding services for weight loss and diabetes solutions.
Tirzepatide, at all doses, had higher risks of AE-related discontinuation than insulin
